1. Home /
    2. Altai Protocol Library /
  2. New Indication: Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (UCS)

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (UCS)

New Indication: Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (UCS)
Study:
  • Phase II, multicenter, single-arm study (STATICE)
  • Pretreated advanced or recurrent HER2-expressing UCS
  • Trastuzumab Deruxtecan: her2 1+ (low group, n=10) vs. her2 ≥2+ (high group, n=22)
Efficacy:
  • ORR: 68% vs. 54.5% (low and high group, respectively)
  • DoR: 8.1 vs. 6.9 mos
  • mPFS: 6.7 vs. 6.2 mos
  • mOS: NR vs. 13.3 mos
Safety:
  • Any grade: Nausea (84.55), anemia (54.5%), leucopenia (51.5%), neutropenia (48%)
  • Grade≥3 AEs: Anemia (24.2%), neutropenia (21.2%), hypoalbuminemia (12.1%)

J Clin Oncol 2023; 28 MAR

Nishikawa Tadaaki et al. Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial

http://doi.org/10.1200/JCO.22.02558

Reviewed by Elvin CHALABİYEV, MD on APR 17, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More